Premium
Molecular testing for JAK 2, MPL , and CALR in myeloproliferative neoplasms
Author(s) -
Xia Daniel,
Hasserjian Robert P.
Publication year - 2016
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.24578
Subject(s) - essential thrombocythemia , myelofibrosis , polycythemia vera , mutation , ruxolitinib , medicine , phenotype , cancer research , biology , gene , genetics , bone marrow
Polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) are myeloproliferative neoplasms characterized by recurrent somatic mutations in JAK2 , CALR , and MPL . This short review addresses (1) the spectrum of mutations seen in PV, ET, and PMF, (2) the emerging genotype‐phenotype correlations, (3) the current role of molecular testing in disease classification and management, and (4) several important considerations for selecting an appropriate molecular test. In our view, sequential testing algorithms and simultaneous assessment of multiple mutations by next‐generation sequencing are both valid approaches to testing. Am. J. Hematol. 91:1277–1280, 2016. © 2016 Wiley Periodicals, Inc.